Toronto Dominion Bank Sells 156,443 Shares of Eli Lilly and Company (NYSE:LLY)

Toronto Dominion Bank reduced its stake in shares of Eli Lilly and Company (NYSE:LLYGet Rating) by 23.9% in the first quarter, HoldingsChannel reports. The firm owned 499,023 shares of the company’s stock after selling 156,443 shares during the period. Toronto Dominion Bank’s holdings in Eli Lilly and were worth $142,899,000 as of its most recent SEC filing.

Other hedge funds have also recently made changes to their positions in the company. Icapital Wealth LLC purchased a new stake in shares of Eli Lilly and during the 1st quarter worth $28,000. AllSquare Wealth Management LLC purchased a new stake in Eli Lilly and in the fourth quarter valued at about $28,000. HWG Holdings LP purchased a new stake in Eli Lilly and in the fourth quarter valued at about $28,000. Leverty Financial Group LLC purchased a new stake in Eli Lilly and in the fourth quarter valued at about $29,000. Finally, FSB Premier Wealth Management Inc. purchased a new stake in Eli Lilly and in the fourth quarter valued at about $30,000. 82.75% of the stock is currently owned by hedge funds and other institutional investors.

Insider Transactions at Eli Lilly and

In related news, CAO Donald A. Zakrowski sold 1,000 shares of Eli Lilly and stock in a transaction that occurred on Wednesday, June 1st. The stock was sold at an average price of $313.44, for a total transaction of $313,440.00. Following the transaction, the chief accounting officer now owns 6,274 shares in the company, valued at $1,966,522.56. The sale was disclosed in a document filed with the SEC, which is accessible through this link. In other Eli Lilly and news, major shareholder Lilly Endowment Inc sold 700 shares of Eli Lilly and stock in a transaction on Wednesday, May 18th. The stock was sold at an average price of $302.00, for a total value of $211,400.00. Following the sale, the insider now owns 105,472,666 shares in the company, valued at $31,852,745,132. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, CAO Donald A. Zakrowski sold 1,000 shares of Eli Lilly and stock in a transaction on Wednesday, June 1st. The shares were sold at an average price of $313.44, for a total value of $313,440.00. Following the completion of the sale, the chief accounting officer now directly owns 6,274 shares of the company’s stock, valued at $1,966,522.56. The disclosure for this sale can be found here. Insiders have sold 1,195,396 shares of company stock valued at $380,134,601 over the last ninety days. Insiders own 0.12% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities research analysts have commented on the company. JPMorgan Chase & Co. increased their price target on Eli Lilly and from $340.00 to $355.00 in a research note on Wednesday, June 1st. Barclays raised their price objective on Eli Lilly and from $333.00 to $355.00 and gave the stock an “overweight” rating in a research note on Thursday, July 7th. Morgan Stanley raised their price objective on Eli Lilly and from $369.00 to $395.00 and gave the stock an “overweight” rating in a research note on Friday, July 8th. Wells Fargo & Company raised their price objective on Eli Lilly and from $280.00 to $305.00 in a research note on Friday, April 29th. Finally, Mizuho raised their price objective on Eli Lilly and from $315.00 to $356.00 in a research note on Monday, May 2nd. Three investment analysts have rated the stock with a hold rating and sixteen have issued a buy rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $316.06.

Eli Lilly and Price Performance

LLY traded down $0.07 during trading on Tuesday, hitting $302.43. The company’s stock had a trading volume of 16,304 shares, compared to its average volume of 2,537,060. The company has a current ratio of 1.10, a quick ratio of 0.85 and a debt-to-equity ratio of 1.70. Eli Lilly and Company has a twelve month low of $220.20 and a twelve month high of $335.33. The business’s fifty day simple moving average is $315.68 and its 200 day simple moving average is $290.06. The firm has a market capitalization of $287.36 billion, a price-to-earnings ratio of 48.25, a P/E/G ratio of 2.25 and a beta of 0.35.

Eli Lilly and (NYSE:LLYGet Rating) last issued its quarterly earnings data on Thursday, August 4th. The company reported $1.25 EPS for the quarter, missing the consensus estimate of $1.86 by ($0.61). Eli Lilly and had a net margin of 19.58% and a return on equity of 85.58%. The business had revenue of $6.49 billion during the quarter, compared to analyst estimates of $6.85 billion. During the same period in the previous year, the business posted $1.87 earnings per share. The firm’s revenue for the quarter was down 3.7% on a year-over-year basis. On average, equities research analysts forecast that Eli Lilly and Company will post 7.98 EPS for the current fiscal year.

Eli Lilly and Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Friday, September 9th. Stockholders of record on Monday, August 15th will be paid a $0.98 dividend. This represents a $3.92 dividend on an annualized basis and a dividend yield of 1.30%. The ex-dividend date of this dividend is Friday, August 12th. Eli Lilly and’s dividend payout ratio is presently 62.52%.

Eli Lilly and Profile

(Get Rating)

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes.

Read More

Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Company (NYSE:LLYGet Rating).

Institutional Ownership by Quarter for Eli Lilly and (NYSE:LLY)

Receive News & Ratings for Eli Lilly and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and and related companies with MarketBeat.com's FREE daily email newsletter.